MedTrace Logo

Improving Function, Quality of Life, Glycemia in Diabetics With Dementia

NCT00792662 · Status: WITHDRAWN · Phase: PHASE4 · Type: INTERVENTIONAL

Last updated 2024-09-23

No results posted yet for this study

Summary

The primary purpose of this study is to determine if the study medication Methylphenidate (Ritalin) will improve subject's blood-sugar control by improving their motivation more than placebo. The secondary objectives of the study are to determine if daily functioning and quality of life improves with methylphenidate treatment.

Conditions

Interventions

DRUG

Methylphenidate

Subject will receive 5mg BID for the first two weeks then 10mg BID until week 16 of the study.

DRUG

Placebo

Standard inactive pill.

Sponsors & Collaborators

Principal Investigators

  • Prasad R Padala, M.D. · University of Nebraska

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
QUADRUPLE
Model
PARALLEL

Eligibility

Min Age
60 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2008-11-18
Primary Completion
2011-12-20
Completion
2011-12-20

More Related Trials

Entities

Drugs
Diseases
Companies

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT00792662 on ClinicalTrials.gov